-
1
-
-
33947732977
-
Angiogenesis: an organizing principle for drug discovery?
-
Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(April (4)):273-286.
-
(2007)
Nat Rev Drug Discov
, vol.6
, Issue.APRIL 4
, pp. 273-286
-
-
Folkman, J.1
-
2
-
-
85013312416
-
Tumor angiogenesis: therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(November (21)):1182-1186.
-
(1971)
N Engl J Med
, vol.285
, Issue.NOVEMBER 21
, pp. 1182-1186
-
-
Folkman, J.1
-
3
-
-
0037376877
-
Angiogenesis and apoptosis
-
Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13(April (2)):159-167.
-
(2003)
Semin Cancer Biol
, vol.13
, Issue.APRIL 2
, pp. 159-167
-
-
Folkman, J.1
-
4
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(June (23)):2335-2342.
-
(2004)
N Engl J Med
, vol.350
, Issue.JUNE 23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
5
-
-
33646448005
-
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
-
Motzer R.J., Hoosen S., Bello C.L., Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006, 15(May (5)):553-561.
-
(2006)
Expert Opin Investig Drugs
, vol.15
, Issue.MAY 5
, pp. 553-561
-
-
Motzer, R.J.1
Hoosen, S.2
Bello, C.L.3
Christensen, J.G.4
-
6
-
-
79952543555
-
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
-
Keisner S.V., Shah S.R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71(March (4)):443-454.
-
(2011)
Drugs
, vol.71
, Issue.MARCH 4
, pp. 443-454
-
-
Keisner, S.V.1
Shah, S.R.2
-
7
-
-
77954781214
-
Sorafenib: a clinical and pharmacologic review
-
Iyer R., Fetterly G., Lugade A., Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010, 11(August (11)):1943-1955.
-
(2010)
Expert Opin Pharmacother
, vol.11
, Issue.AUGUST 11
, pp. 1943-1955
-
-
Iyer, R.1
Fetterly, G.2
Lugade, A.3
Thanavala, Y.4
-
8
-
-
84860389208
-
Vandetanib (ZD6474) in the treatment of medullary thyroid cancer
-
Deshpande H., Roman S., Thumar J., Sosa J.A. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin Med Insights Oncol 2011, July (5):213-221. 10.4137/CMO.S6197.213-21.
-
(2011)
Clin Med Insights Oncol
, vol.JULY
, Issue.5
, pp. 213-221
-
-
Deshpande, H.1
Roman, S.2
Thumar, J.3
Sosa, J.A.4
-
9
-
-
84865253075
-
Concise drug review: pazopanib and axitinib
-
van Geel R.M., Beijnen J.H., Schellens J.H. Concise drug review: pazopanib and axitinib. Oncologist 2012, 17(August (8)):1081-1089.
-
(2012)
Oncologist
, vol.17
, Issue.AUGUST 8
, pp. 1081-1089
-
-
van Geel, R.M.1
Beijnen, J.H.2
Schellens, J.H.3
-
10
-
-
84863691378
-
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
-
Singh M., Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2012, 30(July (7)):648-657.
-
(2012)
Nat Biotechnol
, vol.30
, Issue.JULY 7
, pp. 648-657
-
-
Singh, M.1
Ferrara, N.2
-
11
-
-
79955641941
-
Vaccines targeting the neovasculature of tumors
-
Matejuk A., Leng Q., Chou S.T., Mixson A.J. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011, 3(1):7.
-
(2011)
Vasc Cell
, vol.3
, Issue.1
, pp. 7
-
-
Matejuk, A.1
Leng, Q.2
Chou, S.T.3
Mixson, A.J.4
-
12
-
-
33646174504
-
Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy
-
Okaji Y., Tsuno N.H., Saito S., Yoneyama S., Tanaka M., Nagawa H., et al. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006, 32(May (4)):363-370.
-
(2006)
Eur J Surg Oncol
, vol.32
, Issue.MAY 4
, pp. 363-370
-
-
Okaji, Y.1
Tsuno, N.H.2
Saito, S.3
Yoneyama, S.4
Tanaka, M.5
Nagawa, H.6
-
13
-
-
44249087196
-
Anti-angiogenic active immunotherapy: a new approach to cancer treatment
-
Pan J., Jin P., Yan J., Kabelitz D. Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 2008, 57(August (8)):1105-1114.
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.AUGUST 8
, pp. 1105-1114
-
-
Pan, J.1
Jin, P.2
Yan, J.3
Kabelitz, D.4
-
15
-
-
0035949593
-
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen
-
Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A 2001, 98(September (20)):11545-11550.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.SEPTEMBER 20
, pp. 11545-11550
-
-
Wei, Y.Q.1
Huang, M.J.2
Yang, L.3
Zhao, X.4
Tian, L.5
Lu, Y.6
-
16
-
-
38049071219
-
Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice
-
Li X.H., Tang L., Liu D., Sun H.M., Zhou C.C., Tan L.S., et al. Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 2006, October (25)(10):1221-1226.
-
(2006)
Ai Zheng
, Issue.10 OCTOBER 25
, pp. 1221-1226
-
-
Li, X.H.1
Tang, L.2
Liu, D.3
Sun, H.M.4
Zhou, C.C.5
Tan, L.S.6
-
17
-
-
33847673267
-
Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice
-
Bequet-Romero M., Ayala M., Acevedo B.E., Rodriguez E.G., Ocejo O.L., Torrens I., et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 2007, 10(1):23-34.
-
(2007)
Angiogenesis
, vol.10
, Issue.1
, pp. 23-34
-
-
Bequet-Romero, M.1
Ayala, M.2
Acevedo, B.E.3
Rodriguez, E.G.4
Ocejo, O.L.5
Torrens, I.6
-
18
-
-
33847326301
-
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases
-
Rad F.H., Le B.H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007, 104(February (8)):2837-2842.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, Issue.FEBRUARY 8
, pp. 2837-2842
-
-
Rad, F.H.1
Le, B.H.2
Paturance, S.3
Larcier, P.4
Genne, P.5
Ryffel, B.6
-
19
-
-
34248592407
-
Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma
-
Kamstock D., Elmslie R., Thamm D., Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007, 56(August (8)):1299-1309.
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.AUGUST 8
, pp. 1299-1309
-
-
Kamstock, D.1
Elmslie, R.2
Thamm, D.3
Dow, S.4
-
20
-
-
58149351409
-
Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants
-
Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008, 11(4):381-393.
-
(2008)
Angiogenesis
, vol.11
, Issue.4
, pp. 381-393
-
-
Morera, Y.1
Bequet-Romero, M.2
Ayala, M.3
Lamdan, H.4
Agger, E.M.5
Andersen, P.6
-
21
-
-
84857457850
-
CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors
-
Bequet-Romero M., Morera Y., Ayala-Avila M., Ancizar J., Soria Y., Blanco A., et al. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. Vaccine 2012, 30(February (10)):1790-1799.
-
(2012)
Vaccine
, vol.30
, Issue.FEBRUARY 10
, pp. 1790-1799
-
-
Bequet-Romero, M.1
Morera, Y.2
Ayala-Avila, M.3
Ancizar, J.4
Soria, Y.5
Blanco, A.6
-
22
-
-
77950628629
-
Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates
-
Morera Y., Bequet-Romero M., Ayala M., Velazco J.C., Perez P.P., Alba J.S., et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010, 28(April (19)):3453-3461.
-
(2010)
Vaccine
, vol.28
, Issue.APRIL 19
, pp. 3453-3461
-
-
Morera, Y.1
Bequet-Romero, M.2
Ayala, M.3
Velazco, J.C.4
Perez, P.P.5
Alba, J.S.6
-
23
-
-
84355161453
-
Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates
-
Morera Y., Bequet-Romero M., Ayala M., Perez P.P., Castro J., Sanchez J., et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012, 30(January (2)):368-377.
-
(2012)
Vaccine
, vol.30
, Issue.JANUARY 2
, pp. 368-377
-
-
Morera, Y.1
Bequet-Romero, M.2
Ayala, M.3
Perez, P.P.4
Castro, J.5
Sanchez, J.6
-
24
-
-
70350002279
-
Adverse effects of anticancer agents that target the VEGF pathway
-
Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6(August (8)):465-477.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.AUGUST 8
, pp. 465-477
-
-
Chen, H.X.1
Cleck, J.N.2
-
25
-
-
77956072936
-
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study
-
Kozloff M.F., Berlin J., Flynn P.J., Kabbinavar F., Ashby M., Dong W., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339.
-
(2010)
Oncology
, vol.78
, Issue.5-6
, pp. 329-339
-
-
Kozloff, M.F.1
Berlin, J.2
Flynn, P.J.3
Kabbinavar, F.4
Ashby, M.5
Dong, W.6
-
26
-
-
84867577603
-
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
-
Nakayama G., Uehara K., Ishigure K., Yokoyama H., Ishiyama A., Eguchi T., et al. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol 2012, 70(October (4)):575-581.
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, Issue.OCTOBER 4
, pp. 575-581
-
-
Nakayama, G.1
Uehara, K.2
Ishigure, K.3
Yokoyama, H.4
Ishiyama, A.5
Eguchi, T.6
-
27
-
-
84873619713
-
Targeted anti-vascular therapies for ovarian cancer: current evidence
-
Hall M., Gourley C., McNeish I., Ledermann J., Gore M., Jayson G., et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013, 108(February (2)):250-258.
-
(2013)
Br J Cancer
, vol.108
, Issue.FEBRUARY 2
, pp. 250-258
-
-
Hall, M.1
Gourley, C.2
Mcneish, I.3
Ledermann, J.4
Gore, M.5
Jayson, G.6
-
28
-
-
38749147680
-
Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy
-
Okaji Y., Tsuno N.H., Tanaka M., Yoneyama S., Matsuhashi M., Kitayama J., et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008, 44(February (3)):383-390.
-
(2008)
Eur J Cancer
, vol.44
, Issue.FEBRUARY 3
, pp. 383-390
-
-
Okaji, Y.1
Tsuno, N.H.2
Tanaka, M.3
Yoneyama, S.4
Matsuhashi, M.5
Kitayama, J.6
-
29
-
-
78651391336
-
Gastrointestinal bleeding during antiangiogenic peptide vaccination in combination with gembcitabine for advanced pancreatic cancer
-
Nagayama H., Kazufumi M., Nayuki I., Hideki O., Naoyuki T., Takashi N. Gastrointestinal bleeding during antiangiogenic peptide vaccination in combination with gembcitabine for advanced pancreatic cancer. Clin J Gastroenterol 2010, 706. 10.1007/s12328-010-0178-5.
-
(2010)
Clin J Gastroenterol
, vol.706
-
-
Nagayama, H.1
Kazufumi, M.2
Nayuki, I.3
Hideki, O.4
Naoyuki, T.5
Takashi, N.6
-
30
-
-
84876420644
-
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
-
Yoshimura K., Minami T., Nozawa M., Uemura H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer 2013, 108(April (6)):1260-1266.
-
(2013)
Br J Cancer
, vol.108
, Issue.APRIL 6
, pp. 1260-1266
-
-
Yoshimura, K.1
Minami, T.2
Nozawa, M.3
Uemura, H.4
-
31
-
-
84865204316
-
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-receptor 2 in patients with stage IV and locally advanced pancreatic cancer
-
Niethammer A.G., Lubenau H., Mikus G., Knebel P., Hohmann N., Leowardi C., et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012, 12(August):361. 10.1186/1471-2407-12-361.
-
(2012)
BMC Cancer
, vol.12
, Issue.AUGUST
, pp. 361
-
-
Niethammer, A.G.1
Lubenau, H.2
Mikus, G.3
Knebel, P.4
Hohmann, N.5
Leowardi, C.6
-
32
-
-
75649099783
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
-
Miyazawa M., Ohsawa R., Tsunoda T., Hirono S., Kawai M., Tani M., et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010, 101(February (2)):433-439.
-
(2010)
Cancer Sci
, vol.101
, Issue.FEBRUARY 2
, pp. 433-439
-
-
Miyazawa, M.1
Ohsawa, R.2
Tsunoda, T.3
Hirono, S.4
Kawai, M.5
Tani, M.6
-
33
-
-
30444446808
-
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells
-
de L.J., Fernandez A., Mesa C., Clavel M., Fernandez L.E. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006, 55(April (4)):443-450.
-
(2006)
Cancer Immunol Immunother
, vol.55
, Issue.APRIL 4
, pp. 443-450
-
-
de, L.J.1
Fernandez, A.2
Mesa, C.3
Clavel, M.4
Fernandez, L.E.5
-
34
-
-
79251551682
-
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant
-
Fernandez A., Mesa C., Marigo I., Dolcetti L., Clavell M., Oliver L., et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011, 186(January (1)):264-274.
-
(2011)
J Immunol
, vol.186
, Issue.JANUARY 1
, pp. 264-274
-
-
Fernandez, A.1
Mesa, C.2
Marigo, I.3
Dolcetti, L.4
Clavell, M.5
Oliver, L.6
-
35
-
-
3843071048
-
Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation
-
AUGUST 23-24
-
Mesa C., de L.J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22(August (23-24)):3045-3052.
-
(2004)
Vaccine
, vol.22
, pp. 3045-3052
-
-
Mesa, C.1
de, L.J.2
Rigley, K.3
Fernandez, L.E.4
-
36
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(January (2)):228-247.
-
(2009)
Eur J Cancer
, vol.45
, Issue.JANUARY 2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
37
-
-
77955551910
-
Response definition criteria for ELISPOT assays revisited
-
Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Lower M., et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59(October (10)):1489-1501.
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.OCTOBER 10
, pp. 1489-1501
-
-
Moodie, Z.1
Price, L.2
Gouttefangeas, C.3
Mander, A.4
Janetzki, S.5
Lower, M.6
-
38
-
-
80555129210
-
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories
-
Moodie Z., Price L., Janetzki S., Britten C.M. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 2012, 792:185-196.
-
(2012)
Methods Mol Biol
, vol.792
, pp. 185-196
-
-
Moodie, Z.1
Price, L.2
Janetzki, S.3
Britten, C.M.4
-
39
-
-
79953750263
-
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
-
Britten C.M., Janetzki S., van der Burg S.H., Huber C., Kalos M., Levitsky H.I., et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2011, 60(January (1)):15-22.
-
(2011)
Cancer Immunol Immunother
, vol.60
, Issue.JANUARY 1
, pp. 15-22
-
-
Britten, C.M.1
Janetzki, S.2
van der Burg, S.H.3
Huber, C.4
Kalos, M.5
Levitsky, H.I.6
-
40
-
-
0034212632
-
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
-
Adams J., Carder P.J., Downey S., Forbes M.A., MacLennan K., Allgar V., et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000, 60(June (11)):2898-2905.
-
(2000)
Cancer Res
, vol.60
, Issue.JUNE 11
, pp. 2898-2905
-
-
Adams, J.1
Carder, P.J.2
Downey, S.3
Forbes, M.A.4
Maclennan, K.5
Allgar, V.6
-
41
-
-
0035990391
-
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study
-
Bada A., Casaco P.A., Arteaga M., Martinez J., Leon A., Santana E., et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Hum Exp Toxicol 2002, 21(May (5)):263-267.
-
(2002)
Hum Exp Toxicol
, vol.21
, Issue.MAY 5
, pp. 263-267
-
-
Bada, A.1
Casaco, P.A.2
Arteaga, M.3
Martinez, J.4
Leon, A.5
Santana, E.6
-
42
-
-
7444262837
-
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity
-
Guthmann M.D., Bitton R.J., Carnero A.J., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 2004, 27(November (6)):442-451.
-
(2004)
J Immunother
, vol.27
, Issue.NOVEMBER 6
, pp. 442-451
-
-
Guthmann, M.D.1
Bitton, R.J.2
Carnero, A.J.3
Gabri, M.R.4
Cinat, G.5
Koliren, L.6
-
43
-
-
84897114321
-
An alternative clinical trial for early cancer vaccine development to phase 3+3 design
-
Suppl. 2578
-
Gammoh E., Rahma O.E., Simon R., Khleif S. An alternative clinical trial for early cancer vaccine development to phase 3+3 design. J Clin Oncol (Meeting Abs) 2012, 30(15). Suppl. 2578.
-
(2012)
J Clin Oncol (Meeting Abs)
, vol.30
, Issue.15
-
-
Gammoh, E.1
Rahma, O.E.2
Simon, R.3
Khleif, S.4
-
44
-
-
0141891468
-
Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
-
Rentzsch C., Kayser S., Stumm S., Watermann I., Walter S., Stevanovic S., et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 2003, 9(October (12)):4376-4386.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.OCTOBER 12
, pp. 4376-4386
-
-
Rentzsch, C.1
Kayser, S.2
Stumm, S.3
Watermann, I.4
Walter, S.5
Stevanovic, S.6
-
46
-
-
78349289653
-
The SSX family of cancer-testis antigens as target proteins for tumor therapy
-
[Epub@2010 Oct 11: 150591]
-
Smith H.A., McNeel D.G. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010, 2010:150591. [Epub@2010 Oct 11: 150591]. 10.1155/2010/150591.
-
(2010)
Clin Dev Immunol
, vol.2010
, pp. 150591
-
-
Smith, H.A.1
Mcneel, D.G.2
-
47
-
-
35649005398
-
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
-
Morse M.A., Hobeika A., Osada T., Niedzwiecki D., Marcom P.K., Blackwell K.L., et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007, 5(September):42.
-
(2007)
J Transl Med
, vol.5
, Issue.SEPTEMBER
, pp. 42
-
-
Morse, M.A.1
Hobeika, A.2
Osada, T.3
Niedzwiecki, D.4
Marcom, P.K.5
Blackwell, K.L.6
-
48
-
-
84860188105
-
Therapeutic cancer vaccines: current status and moving forward
-
Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104(April (8)):599-613.
-
(2012)
J Natl Cancer Inst
, vol.104
, Issue.APRIL 8
, pp. 599-613
-
-
Schlom, J.1
-
49
-
-
34347381738
-
Cancer vaccines: a promising cancer therapy against all odds
-
Silk A.W., Finn O.J. Cancer vaccines: a promising cancer therapy against all odds. Fut Oncol 2007, 3(June (3)):299-306.
-
(2007)
Fut Oncol
, vol.3
, Issue.JUNE 3
, pp. 299-306
-
-
Silk, A.W.1
Finn, O.J.2
-
50
-
-
34447136106
-
Cancer vaccines: moving beyond current paradigms
-
Schlom J., Arlen P.M., Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007, 13(July (13)):3776-3782.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.JULY 13
, pp. 3776-3782
-
-
Schlom, J.1
Arlen, P.M.2
Gulley, J.L.3
-
51
-
-
46949084994
-
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
-
Sessa C., Guibal A., Del C.G., Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol 2008, 5(July (7)):378-391.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.JULY 7
, pp. 378-391
-
-
Sessa, C.1
Guibal, A.2
Del, C.G.3
Ruegg, C.4
-
52
-
-
77954944628
-
Normal ranges of angiogenesis regulatory proteins in human platelets
-
Peterson J.E., Zurakowski D., Italiano J.E., Michel L.V., Fox L., Klement G.L., et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010, 85(July (7)):487-493.
-
(2010)
Am J Hematol
, vol.85
, Issue.JULY 7
, pp. 487-493
-
-
Peterson, J.E.1
Zurakowski, D.2
Italiano, J.E.3
Michel, L.V.4
Fox, L.5
Klement, G.L.6
-
53
-
-
33845247353
-
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
-
Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(December (11)):1474-1482.
-
(2006)
Br J Cancer
, vol.95
, Issue.DECEMBER 11
, pp. 1474-1482
-
-
Bernhardt, S.L.1
Gjertsen, M.K.2
Trachsel, S.3
Moller, M.4
Eriksen, J.A.5
Meo, M.6
-
54
-
-
49149117772
-
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
-
Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008, 26(July (20)):3426-3433.
-
(2008)
J Clin Oncol
, vol.26
, Issue.JULY 20
, pp. 3426-3433
-
-
Holmes, J.P.1
Benavides, L.C.2
Gates, J.D.3
Carmichael, M.G.4
Hueman, M.T.5
Mittendorf, E.A.6
-
55
-
-
3042745485
-
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine
-
Disis M.L., Schiffman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004, 22(May (10)):1916-1925.
-
(2004)
J Clin Oncol
, vol.22
, Issue.MAY 10
, pp. 1916-1925
-
-
Disis, M.L.1
Schiffman, K.2
Guthrie, K.3
Salazar, L.G.4
Knutson, K.L.5
Goodell, V.6
-
56
-
-
56749170720
-
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
-
Perales M.A., Yuan J., Powel S., Gallardo H.F., Rasalan T.S., Gonzalez C., et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008, 16(December (12)):2022-2029.
-
(2008)
Mol Ther
, vol.16
, Issue.DECEMBER 12
, pp. 2022-2029
-
-
Perales, M.A.1
Yuan, J.2
Powel, S.3
Gallardo, H.F.4
Rasalan, T.S.5
Gonzalez, C.6
-
57
-
-
0033153564
-
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial
-
van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35(June (6)):946-952.
-
(1999)
Eur J Cancer
, vol.35
, Issue.JUNE 6
, pp. 946-952
-
-
van Driel, W.J.1
Ressing, M.E.2
Kenter, G.G.3
Brandt, R.M.4
Krul, E.J.5
van Rossum, A.B.6
-
58
-
-
84867811471
-
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
-
Berinstein N.L., Karkada M., Morse M.A., Nemunaitis J.J., Chatta G., Kaufman H., et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012, 10:156.
-
(2012)
J Transl Med
, vol.10
, pp. 156
-
-
Berinstein, N.L.1
Karkada, M.2
Morse, M.A.3
Nemunaitis, J.J.4
Chatta, G.5
Kaufman, H.6
-
59
-
-
69049089548
-
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
-
Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15(September (17)):5323-5337.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.SEPTEMBER 17
, pp. 5323-5337
-
-
Cheever, M.A.1
Allison, J.P.2
Ferris, A.S.3
Finn, O.J.4
Hastings, B.M.5
Hecht, T.T.6
-
60
-
-
84877945468
-
Immune system targeting by biodegradable nanoparticles for cancer vaccines
-
Silva J.M., Videira M., Gaspar R., Preat V., Florindo H.F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013, 168(June (2)):179-199.
-
(2013)
J Control Release
, vol.168
, Issue.JUNE 2
, pp. 179-199
-
-
Silva, J.M.1
Videira, M.2
Gaspar, R.3
Preat, V.4
Florindo, H.F.5
-
61
-
-
84858797296
-
The determinants of tumour immunogenicity
-
Blankenstein T., Coulie P.G., Gilboa E., Jaffee E.M. The determinants of tumour immunogenicity. Nat Rev Cancer 2012, 12(March (4)):307-313.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.MARCH 4
, pp. 307-313
-
-
Blankenstein, T.1
Coulie, P.G.2
Gilboa, E.3
Jaffee, E.M.4
-
62
-
-
84991035719
-
Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation
-
Vatsan R., Bross P., Liu K., Theoret M., De Claro A., Lu J., et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J Immunother Cancer 2013, 1(1):5.
-
(2013)
J Immunother Cancer
, vol.1
, Issue.1
, pp. 5
-
-
Vatsan, R.1
Bross, P.2
Liu, K.3
Theoret, M.4
De Claro, A.5
Lu, J.6
|